



## Antibody–Drug Conjugates and Cancer Immunotherapy

Guest Editor:

**Dr. Sofia Genta**

Kingston Health Sciences Centre,  
Kingston, ON K7L 2V7, Canada

Deadline for manuscript  
submissions:

**25 October 2024**

### Message from the Guest Editor

Dear Colleagues,

Antibody–drug conjugates (ADCs) are powerful anticancer agents designed for target delivery of cytotoxic molecules. Several studies indicate that ADCs have immunostimulatory properties through different mechanisms, including macrophage reprogramming and T memory cell generation. These observations led to growing interest in the development of ADCs specifically designed to boost the immune response through the delivery of immuno-stimulant payloads or by targeting the tumor microenvironment. Despite this, many questions remain open: can immuno-stimulant ADCs induce a response in "cold tumors", refractory to immune checkpoint inhibitors? Can ADCs revert immunotherapy resistance? Do ADCs and immunotherapy agents have a synergistic effect? Is there an optimal sequence for treatment in cancers with known sensitivity to ADCs and immunotherapy? The publication of a Special Issue may facilitate solutions to some of these questions and support the development of effective treatment strategies for cancer patients.

Dr. Sofia Genta  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)